The cardiovascular safety of celecoxib.
Danny Liew, Henry Krum
Future Cardiology | Published : 2005
Ever since the VIoxx Gastrointestinal Outcomes Research (VIGOR) trial first suggested that rofecoxib may increase the risk of cardiovascular disease, and especially since it was withdrawn from the market based on mounting evidence of this risk, celecoxib has had to bear intense scrutiny regarding its own potential cardiovascular effects. This article reviews the current body of evidence regarding the cardiovascular effects of celecoxib, considered under two distinct, but non-mutually exclusive, headings: cardiorenal and thromboembolic. In terms of cardiorenal effects, celecoxib appears to cause a slight increase in blood pressure, and probably to the same extent as nonselective nonsteroidal ..View full abstract